Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Optimaliseren van behandeling en follow-up bij plaveiselcelcarcinoom van de vulva
okt 2019 | Gynaecologische oncologie